Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr;72(4):e31516.
doi: 10.1002/pbc.31516. Epub 2025 Jan 23.

Access to CARe: A Narrative of Real-World Medical Decision-Making to Access Chimeric Antigen Receptor (CAR) T-Cell Therapy in Children, Adolescents, and Young Adults

Angela Steineck  1 , Karen Chao  2 , Anurekha G Hall  3 , Elad Jacoby  4 , Allison Barz Leahy  5 , John A Ligon  6 , Katia Luciani  7 , Liora M Schultz  2 , Corinne N Summers  3 , Lisa Ward  8 , Lena E Winestone  9 , Nirali N Shah  10
Affiliations
Review

Access to CARe: A Narrative of Real-World Medical Decision-Making to Access Chimeric Antigen Receptor (CAR) T-Cell Therapy in Children, Adolescents, and Young Adults

Angela Steineck et al. Pediatr Blood Cancer. 2025 Apr.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is a potentially life-saving treatment for children with relapsed/refractory B-cell hematologic malignancies, and remains an important investigational therapy for other childhood cancers. Yet, access to this class of therapies remains suboptimal through both commercial use and clinical trials, especially in children, adolescents, and young adults. Using a series of case-based discussions, we outline guidance on real-world medical decision-making, and offer potential solutions to enhancing access to CAR T-cell therapy as a treatment modality.

Keywords: general; immunotherapy; oncology; psychosocial; support care.

PubMed Disclaimer

References

    1. N. N. A. Howlader, M. Krapcho, D. Miller, et al., SEER Cancer Statistics Review (CSR) (US: NCI, NIH, November 2019), https://seer.cancer.gov/csr/1975_2017/.
    1. T. W. Laetsch, S. L. Maude, S. Rives, et al., “Three‐Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial,” Journal of Clinical Oncology 41, no. 9 (2023): 1664–1669, https://doi.org/10.1200/JCO.22.00642.
    1. S. L. Maude, “Tisagenlecleucel in Pediatric Patients With Acute Lymphoblastic Leukemia,” Clinical Advances in Hematology & Oncology 16, no. 10 (2018): 664–666.
    1. N. N. Shah, D. W. Lee, B. Yates, et al., “Long‐Term Follow‐Up of CD19‐CAR T‐Cell Therapy in Children and Young Adults With B‐ALL,” Journal of Clinical Oncology 39, no. 15 (2021): 1650–1659, https://doi.org/10.1200/JCO.20.02262.
    1. M. D. Whittington, R. B. McQueen, D. A. Ollendorf, et al., “Long‐Term Survival and Value of Chimeric Antigen Receptor T‐Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia,” JAMA Pediatrics 172, no. 12 (2018): 1161–1168, https://doi.org/10.1001/jamapediatrics.2018.2530.

Substances

LinkOut - more resources